Frankfurt - Delayed Quote EUR

Ocumension Therapeutics (5DG.F)

Compare
0.5200
0.0000
(0.00%)
As of 8:05:02 AM GMT+1. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Ye Liu CEO & Executive Director 785.75k -- 1971
Dr. Zhaopeng Hu Chief Development Officer & Executive Director 292.06k -- 1973
Mr. Tim Ruan CFO & Joint Company Secretary -- -- 1986
Dr. DongHong Chen Chief Medical Officer -- -- 1971
Mr. Qinglei Zuo Chief Commercial Officer -- -- 1984
Dr. NA NA Chief Medical Officer -- -- --
Ms. Tingchan Chen Joint Company Secretary -- -- 1995

Ocumension Therapeutics

No. 1858 Yinzhongnan Road
Guoxiang Subdistrict Wuzhong District
Suzhou
China
https://www.ocumension.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
477

Description

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, blepharitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, acute glaucoma, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. It had various drug assets in its portfolio. The company was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.

Corporate Governance

Ocumension Therapeutics’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

6622.HK Zhaoke Ophthalmology Limited
1.390
+0.72%
 
DNTH Dianthus Therapeutics, Inc.
21.77
+4.36%
 
VRDN Viridian Therapeutics, Inc.
20.08
+3.35%
 
EYPT EyePoint Pharmaceuticals, Inc.
8.05
+4.14%
 
VIGL Vigil Neuroscience, Inc.
2.3500
+7.31%
 
SAVA Cassava Sciences, Inc.
2.3800
+3.03%